PARIS, France I January 15, 2019 I Biomunex Pharmaceuticals, a biopharmaceutical company focused on providing immuno-therapeutics through the discovery and development of bi- and multi-specific antibodies, today announces that it has entered into a licensing agreement with Sanofi. Under the terms of the agreement, Sanofi will have access to Biomunex’ proprietary technology to generate and optimize bi- and multi-specific antibody therapeutics. Sanofi will be solely responsible for the research, development, manufacturing and global commercialization activities. This agreement, the first of its kind for Biomunex, is in line with the company’s business model, which is to establish licensing or collaboration agreements and to become a clinical-stage company in the short term.
Biomunex will receive an initial upfront payment and will be eligible to receive further clinical, regulatory and commercial milestone payments. Further financial details were not disclosed.
“This licensing agreement is a major milestone for Biomunex. It demonstrates the high value of the BiXAb® technology and is the starting point for our collaboration strategy with pharmaceutical companies to discover and develop cutting-edge bi- and multi-specific antibodies, giving patients new treatment options,” said Pierre-Emmanuel Gerard, MD, founder and CEO of Biomunex. “We believe that the proceeds from this deal, together with the funding round that we expect to finalize in the near future, will help us accelerate the development of Biomunex’ proprietary BiXAb® bi- and multi-specific antibody programs in immuno-oncology and other therapeutic areas towards clinical development.”
About the BiXAb® Platform
Biomunex’ Plug-and-Play BiXAb® platform generates next-generation bi- and multi-specific antibodies. This universal modular bi- and multi-specific format enables turnkey formatting of BiXAb® from any pair of monospecific monoclonal antibodies as building blocks, with minimal engineering, in a timely and cost-effective manner. BiXAb® possesses all the key properties expected of an ideal bi-specific antibody technology (modularity, excellent drug-like properties and manufacturability, multi-specificity potential). This enables Biomunex to develop immuno-oncology drug candidates with high anti-tumor activity demonstrating true synergy on their targets. The BiXAb® platform is also suitable to generate innovative bi- and multi-specific antibodies in other therapeutic areas, such as immune-mediated inflammatory and infectious diseases.
About Biomunex Pharmaceuticals
Biomunex is a biopharmaceutical company focused on providing immuno-therapeutics through the discovery and development of bi- and multi-specific antibodies, created from its next generation proprietary BiXAb® platform. Its most advanced candidate has demonstrated superior in vitro and in vivo efficacy and could become a highly potent immunotherapy for several solid tumors, such as head-and-neck, gastric and pancreatic cancers. Its other lead candidate, which leverages the power of immune checkpoint inhibition, is being evaluated for hematological malignancies and is showing a high therapeutic potential. In collaboration with renowned public institutions in Europe, Biomunex has also initiated the discovery and development of several additional cutting-edge multi-specific antibodies, which will employ novel approaches. www.biomunex.com
SOURCE: Biomunex Pharmaceuticals
Post Views: 238
PARIS, France I January 15, 2019 I Biomunex Pharmaceuticals, a biopharmaceutical company focused on providing immuno-therapeutics through the discovery and development of bi- and multi-specific antibodies, today announces that it has entered into a licensing agreement with Sanofi. Under the terms of the agreement, Sanofi will have access to Biomunex’ proprietary technology to generate and optimize bi- and multi-specific antibody therapeutics. Sanofi will be solely responsible for the research, development, manufacturing and global commercialization activities. This agreement, the first of its kind for Biomunex, is in line with the company’s business model, which is to establish licensing or collaboration agreements and to become a clinical-stage company in the short term.
Biomunex will receive an initial upfront payment and will be eligible to receive further clinical, regulatory and commercial milestone payments. Further financial details were not disclosed.
“This licensing agreement is a major milestone for Biomunex. It demonstrates the high value of the BiXAb® technology and is the starting point for our collaboration strategy with pharmaceutical companies to discover and develop cutting-edge bi- and multi-specific antibodies, giving patients new treatment options,” said Pierre-Emmanuel Gerard, MD, founder and CEO of Biomunex. “We believe that the proceeds from this deal, together with the funding round that we expect to finalize in the near future, will help us accelerate the development of Biomunex’ proprietary BiXAb® bi- and multi-specific antibody programs in immuno-oncology and other therapeutic areas towards clinical development.”
About the BiXAb® Platform
Biomunex’ Plug-and-Play BiXAb® platform generates next-generation bi- and multi-specific antibodies. This universal modular bi- and multi-specific format enables turnkey formatting of BiXAb® from any pair of monospecific monoclonal antibodies as building blocks, with minimal engineering, in a timely and cost-effective manner. BiXAb® possesses all the key properties expected of an ideal bi-specific antibody technology (modularity, excellent drug-like properties and manufacturability, multi-specificity potential). This enables Biomunex to develop immuno-oncology drug candidates with high anti-tumor activity demonstrating true synergy on their targets. The BiXAb® platform is also suitable to generate innovative bi- and multi-specific antibodies in other therapeutic areas, such as immune-mediated inflammatory and infectious diseases.
About Biomunex Pharmaceuticals
Biomunex is a biopharmaceutical company focused on providing immuno-therapeutics through the discovery and development of bi- and multi-specific antibodies, created from its next generation proprietary BiXAb® platform. Its most advanced candidate has demonstrated superior in vitro and in vivo efficacy and could become a highly potent immunotherapy for several solid tumors, such as head-and-neck, gastric and pancreatic cancers. Its other lead candidate, which leverages the power of immune checkpoint inhibition, is being evaluated for hematological malignancies and is showing a high therapeutic potential. In collaboration with renowned public institutions in Europe, Biomunex has also initiated the discovery and development of several additional cutting-edge multi-specific antibodies, which will employ novel approaches. www.biomunex.com
SOURCE: Biomunex Pharmaceuticals
Post Views: 238
